Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings or view top-rated stocks.

1 equities research analysts have issued twelve-month price targets for Supernus Pharmaceuticals' stock. Their SUPN share price forecasts range from $47.00 to $47.00. On average, they anticipate the company's share price to reach $47.00 in the next year. This suggests a possible upside of 11.8% from the stock's current price.
View analysts price targets for SUPN or view top-rated stocks among Wall Street analysts.

Supernus Pharmaceuticals' stock was trading at $35.67 on January 1st, 2023. Since then, SUPN stock has increased by 17.8% and is now trading at $42.03.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 12th 2023.
View our SUPN earnings forecast.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced its earnings results on Tuesday, November, 8th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.32 by $0.29. The specialty pharmaceutical company had revenue of $177.35 million for the quarter, compared to analysts' expectations of $173.22 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 4.51% and a net margin of 5.72%.

Supernus Pharmaceuticals updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $650.00 million-$680.00 million, compared to the consensus revenue estimate of $674.36 million.

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Supernus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (2.97%), Rice Hall James & Associates LLC (1.15%), Congress Asset Management Co. MA (0.94%), International Biotechnology Trust PLC (0.71%), Tributary Capital Management LLC (0.63%) and Scout Investments Inc. (0.57%). Insiders that own company stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends.

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SUPN stock can currently be purchased for approximately $42.03.

Supernus Pharmaceuticals (NASDAQ:SUPN) has a market capitalization of $2.27 billion and generates $579.78 million in revenue each year. The specialty pharmaceutical company earns $53.42 million in net income (profit) each year or $0.64 on an earnings per share basis.

The company employs 575 workers across the globe.

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The official website for the company is www.supernus.com. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at gpatrick@supernus.com, or via fax at 301-838-2501.